18:09 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Akcea's AKCEA-APO(a)-LRx reduces LPA levels in Phase II

Akcea Therapeutics Inc. (NASDAQ:AKCA) said AKCEA-APO(a)-LRx led to significant dose-dependent reductions in lipoprotein(a) (LPA) compared with placebo in a Phase II trial to reduce elevated LPA levels in patients with established cardiovascular disease. The company...
16:44 , Sep 19, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on PKN1, DOK2 and APOB could help predict the risk of pancreatic ductal adenocarcinoma (PDAC) in the Chinese population. In 943 PDAC patients and 3,908 healthy volunteers of Chinese descent, whole-exome screening...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
18:51 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Esperion combo lowers LDL-C in Phase III for high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
18:13 , Aug 31, 2018 |  BC Week In Review  |  Financial News

ApoGen expands series A to $11M

Drug-resistant cancer company ApoGen Biotechnologies Inc. raised an additional $4 million on Aug. 23 from M Ventures and existing investors in its series A round, bringing the round's total to $11 million. M Ventures is...
03:13 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

Amgen's Repatha lowers LDL-C in Phase III for dyslipidemia in Type II diabetics

Amgen Inc. (NASDAQ:AMGN) reported in June that Repatha evolocumab met the co-primary endpoints in the Phase III BANTING trial to treat hypercholesterolemia or mixed dyslipidemia in Type II diabetics taking the maximum tolerated dose of...
20:46 , Aug 13, 2018 |  BC Extra  |  Preclinical News

Polygenic scores increase disease risk prediction

Two studies in...
00:21 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

RegenxBio discloses second serious AE for hypercholesterolemia gene therapy

RegenxBio Inc. (NASDAQ:RGNX) said RGX-501 led to a second treatment-related serious adverse event in a Phase I/II trial to treat homozygous familial hypercholesterolemia (HoFH). The open-label, international trial has enrolled six patients to receive a...
00:01 , Aug 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The...
19:53 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Ironwood reports Phase IIb data of praliciguat to treat diabetes with hypertension

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) reported data from 26 diabetic patients with hypertension in a Phase IIa study showing that compared with placebo praliciguat (IW-1973) reduced blood pressure (6.3 vs. 1.5 mmHg), fasting glucose levels (32.5...